Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$120.40 USD
+1.64 (1.38%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $120.44 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
SRPT 120.40 +1.64(1.38%)
Will SRPT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRPT
Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
Other News for SRPT
Capricor stock rallies 20% on DMD data presentation update
Sarepta Therapeutics (SRPT) Gets a Buy from Piper Sandler
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics
Capital Markets’ top 30 global ideas for the fourth quarter